Related Experiment Video
Updated: Jun 13, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Emerging Tumor-Agnostic Molecular Targets
Dedipya Bhamidipati1, Alison M Schram2
1SUNY Downstate Medical Center, Brooklyn, New York.
Abstract:
Advances in tumor molecular profiling have uncovered shared genomic and proteomic alterations across tumor types that can be exploited therapeutically. A biomarker-driven, disease-agnostic approach to oncology drug development can maximize the reach of novel therapeutics. To date, eight drug-biomarker pairs have been approved for the treatment of patients with advanced solid tumors with specific molecular profiles. Emerging biomarkers with the potential for clinical actionability across tumor types include gene fusions involving NRG1, FGFR1/2/3, BRAF, and ALK and mutations in TP53 Y220C, KRAS G12C, FGFR2/3, and BRAF non-V600 (class II). We explore the growing evidence for clinical actionability of these biomarkers in patients with advanced solid tumors.
Insights
Molecular profiling reveals shared tumor alterations, enabling biomarker-driven, disease-agnostic cancer drug development. This approach expands therapeutic reach for advanced solid tumors with specific molecular profiles.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Tumor molecular profiling identifies common genomic and proteomic alterations across diverse cancer types.
- A disease-agnostic, biomarker-driven strategy enhances the development and accessibility of novel cancer therapeutics.
- Eight drug-biomarker pairs are currently approved for advanced solid tumors with specific molecular signatures.
Purpose of the Study:
- To explore the clinical actionability of emerging biomarkers in patients with advanced solid tumors.
- To highlight the potential of novel therapeutics targeting shared molecular alterations across tumor types.
Main Methods:
- Review of current literature on molecular profiling in oncology.
- Analysis of emerging biomarkers and their therapeutic implications.
- Examination of approved drug-biomarker pairs for advanced solid tumors.
Main Results:
- Shared genomic alterations, including gene fusions (NRG1, FGFR1/2/3, BRAF, ALK) and mutations (TP53 Y220C, KRAS G12C, FGFR2/3, BRAF non-V600), show therapeutic potential.
- The disease-agnostic approach facilitates broader application of targeted therapies.
- Evidence supports the clinical actionability of these biomarkers in various advanced solid tumors.
Conclusions:
- Biomarker-driven, disease-agnostic drug development is a promising strategy in oncology.
- Targeting shared molecular alterations can improve treatment outcomes for patients with advanced solid tumors.
- Continued research into emerging biomarkers will expand therapeutic options.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
